I need to read the filing for substantive financial content beyond the cover page and risk factor summary. The filing text provided cuts off after the risk factor summary, with no financial statements, MD&A figures, or other substantive numerical disclosures included. However, there is enough substantive disclosure content (risk factors, operational disclosures, company details) to exceed 150 words, so I will proceed with what is available.

Arcus Biosciences, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the U.S. Securities and Exchange Commission on November 4, 2026, disclosing operational risks and a share count of 143,990,614 common shares outstanding as of October 29, 2026.

Key Highlights

  • Shares outstanding: As of October 29, 2026, Arcus Biosciences reported 143,990,614 shares of common stock, $0.0001 par value per share, outstanding.
  • Large accelerated filer: The company is classified as a large accelerated filer, according to the filing.
  • No product revenue: The company disclosed it "has never generated any revenue from product sales" and anticipates continuing to incur significant losses.
  • Hercules loan agreement: The filing identifies a loan and security agreement with Hercules Capital, Inc. as a source of operating restrictions via debt covenants.
  • Collaboration dependence: The company disclosed it "expect[s] to depend on collaborations for the development of our investigational products."
  • No shell company: The registrant confirmed it is not a shell company as defined in Rule 12b-2 of the Exchange Act.

Arcus Biosciences Outlines Key Risks in September 2026 Quarterly Disclosure

Arcus Biosciences, Inc. (NYSE:RCUS), a Delaware-incorporated biopharmaceutical company headquartered at 3928 Point Eden Way, Hayward, California 94545, filed its quarterly report on Form 10-Q for the period ended September 30, 2026. The filing confirms the company had 143,990,614 shares of common stock outstanding as of October 29, 2026, and is classified as a large accelerated filer.

According to the filing, the company "has a history of operating losses, has never generated any revenue from product sales and anticipates that we will continue to incur significant losses for the foreseeable future." The registrant also disclosed it may need to obtain additional funding, warning that an inability to raise capital "may be forced to restrict our operations or delay, reduce or eliminate our product development programs." The filing further identifies a loan and security agreement with Hercules Capital, Inc. as placing operating restrictions on the company through associated covenants.

The company's risk factor summary highlights several additional areas of concern disclosed in the filing, including reliance on third parties for clinical trials and research, the absence of guaranteed regulatory approvals across jurisdictions, potential intellectual property challenges, and the need for companion diagnostics for certain investigational products. The filing notes that the full risk factor discussion appears in Part II, Item 1A of the quarterly report. All forward-looking statements in the filing are the company's own and are subject to its cautionary language as described therein.

What Was Disclosed

Arcus Biosciences filed a Form 10-Q for the quarter ended September 30, 2026, disclosing 143,990,614 shares outstanding, continued operating losses with no product sales revenue, a Hercules Capital loan agreement with restrictive covenants, and extensive risk factors related to development, collaboration, and financing.